Eli Lilly has committed an additional $4.5 billion across two manufacturing sites in Lebanon, Indiana, taking its total Indiana capital expansion commitments since 2020 to more than $21 billion. The investment also marks the opening of Lilly Lebanon Advanced Therapies, the company’s first dedicated genetic medicine manufacturing facility.
Eli Lilly has filed six new U.S. lawsuits against sellers in the Eli Lilly retatrutide black market, adding to referrals covering more than 200 entities and 14,000 illegal listings. The drugmaker is calling on platforms and payment firms to help shut down the illegal trade.
Eli Lilly’s Retatrutide has demonstrated record-breaking efficacy in Phase 2 trials, showing that triple-hormone receptor agonists may be the future of chronic weight management.
Eli Lilly and Company announced positive topline results from TRANSCEND-T2D-1, a landmark Phase 3 clinical trial evaluating retatrutide, an investigational triple hormone receptor agonist. The trial results demonstrate [Read More…]
Eli Lilly and Company announced groundbreaking positive topline results from the Phase 3 TRIUMPH-4 clinical trial, confirming its investigational triple-agonist drug, retatrutide, delivered unprecedented weight loss of up to 28.7% (71.2 lbs) and substantial relief from the pain and functional limitations associated with knee osteoarthritis.
